# Successful Co-administration of Dupilumab and Anti-tuberculosis Drugs in a Severely Uncontrolled Asthma Patient With Pulmonary Tuberculosis

## TL;DR

A patient with severe asthma and tuberculosis successfully received dupilumab and anti-TB drugs together, offering a potential treatment approach for similar cases.

## Contribution

This case report presents a successful co-administration of dupilumab and anti-TB drugs in a patient with severe asthma and TB.

## Key findings

- The patient had severe, uncontrolled type 2 allergic asthma and developed pulmonary TB.
- Dupilumab and anti-TB drugs were co-administered successfully without adverse effects.
- The case suggests a viable treatment strategy for similar clinical scenarios.

## Abstract

The co-occurrence of active tuberculosis (TB) in patients with moderate to severe asthma presents unique therapeutic challenges, particularly with the advent of biologics like dupilumab, which targets the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways in asthma treatment. Despite the general safety of biologics, concerns about immunosuppression and susceptibility to infections like TB persist. This case report discusses a male with severe, uncontrolled type 2 allergic asthma, who experienced multiple exacerbations despite maximal bronchodilator therapy and then concomitantly developed pulmonary TB. This case demonstrates a potential clinical scenario for co-administering dupilumab with anti-TB treatment, suggesting a beneficial approach for similar clinical scenarios and contributing to the literature on this topic.